Table 1.
Characteristics of participants analysed, by time point.
| Time point | PCV10 group | PCV13 group | Control group* | p-value | |
|---|---|---|---|---|---|
| Age, months | 2 m | 2.1 (1.9–2.4) | 2.1 (1.9–2.4) | 2.1 (2.0–2.5) | >0.999 |
| 6 m | 6.1 (5.7–6.9) | 6.1 (5.7–7.0) | 6.1 (5.0–6.8) | >0.999 | |
| 9 m | 9.1 (9.0–10.1) | 9.1 (8.8–10.1) | 9.1 (9.0–11.2) | 0.117 | |
| 12 m | 12.1 (12.0–14.0) | 12.1 (11.8–13.1) | 12.1 (12.0–13.2) | >0.999 | |
| 18 m | 18.1 (17.9–20.9) | 18.1 (17.7–20.0) | 18.2 (17.4–20.3) | 0.018 | |
| 24 m | 24.1 (23.9–25.9) | 24.1 (23.6–28.3) | 24.1 (23.4–26.9) | 0.321 | |
| Any current breastfeeding | 2 m | 195/250 (78.0%) | 194/250† (77.6%) | 140/196† (71.4%) | 0.208 |
| 6 m | 129/243 (53.1%) | 117/239 (49.0%) | 91/193 (47.2%) | 0.437 | |
| 9 m | 91/239 (38.1%) | 88/235 (37.4%) | 70/190 (36.8%) | 0.966 | |
| 12 m | 71/231 (30.7%) | 62/230 (27.0%) | 52/188 (27.7%) | 0.637 | |
| 18 m | 30/220† (13.6%) | 28/218 (12.8%) | 52/368 (14.1%) | 0.908 | |
| 24 m | 9/205 (4.4%) | 13/200† (6.5%) | 10/170 (5.9%) | 0.636 | |
| Presence of URTI symptoms | 2 m | 18/250 (7.2%) | 14/251 (5.6%) | 10/197 (5.1%) | 0.603 |
| 6 m | 43/243 (17.7%) | 37/239 (15.5%) | 27/193 (14.0%) | 0.564 | |
| 9 m | 38/239 (15.9%) | 51/235 (21.7%) | 28/190 (14.7%) | 0.118 | |
| 12 m | 50/231 (21.6%) | 44/230 (19.1%) | 34/188 (18.1%) | 0.635 | |
| 18 m | 23/220† (10.5%) | 35/218 (16.1%) | 59/368 (16.0%) | 0.134 | |
| 24 m | 31/205 (15.1%) | 44/200† (22.0%) | 20/170 (11.8%) | 0.024 | |
| Antibiotic use in past fortnight | 2 m | 6/250 (2.4%) | 12/251 (4.8%) | 4/197 (2.0%) | 0.178 |
| 6 m | 21/243 (8.6%) | 21/239 (8.8%) | 17/193 (8.8%) | 0.994 | |
| 9 m | 36/239 (15.1%) | 41/235 (17.4%) | 26/190 (13.7%) | 0.551 | |
| 12 m | 25/231 (10.8%) | 20/230 (8.7%) | 22/188 (11.7%) | 0.575 | |
| 18 m | 28/220† (12.7%) | 25/218 (11.5%) | 59/368 (16.0%) | 0.255 | |
| 24 m | 18/205 (8.8%) | 18/200† (9.0%) | 22/170 (12.9%) | 0.337 | |
| Current antibiotic use | 2 m | 3/250 (1.2%) | 6/251 (2.4%) | 4/197 (2.0%) | 0.602 |
| 6 m | 5/243 (2.1%) | 9/239 (3.8%) | 7/193 (3.6%) | 0.684 | |
| 9 m | 10/239 (4.2%) | 18/235 (7.7%) | 5/190 (2.6%) | 0.047 | |
| 12 m | 17/231 (7.4%) | 14/230 (6.1%) | 14/188 (7.4%) | 0.820 | |
| 18 m | 13/220† (5.9%) | 13/218 (6.0%) | 17/368 (4.6%) | 0.709 | |
| 24 m | 12/205 (5.9%) | 9/200† (4.5%) | 10/170 (5.9%) | 0.788 |
Data are median (range) or n/N (%). p-values based on quantile regression with bootstrapped standard errors (for comparisons of medians) or chi-squared test (for comparisons of proportions). PCV = pneumococcal conjugate vaccine. PCV10 = ten-valent PCV. PCV13 = 13-valent PCV. URTI = upper respiratory tract infection (presence of runny nose and/or cough at the time of swab collection). *Data for controls comes from Group F (2–12 months), Groups F and G combined (18 months), or Group G (24 months). †Data missing for one participant.